VIA Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VIAP research report →
About the company
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes.
- CEO
- Thomas Quertermous
- IPO
- 2007
- Employees
- 6
- HQ
- San Francisco, US
Price Chart
- Market Cap
- $10.28K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -2.39
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 64.66%
- ROIC
- 0.00%
- Revenue
- $0 · 0.00%
- Net Income
- $-9,601,315 · 54.23%
- EPS
- $-0.47 · 55.24%
- Op Income
- $-6,020,941
- FCF YoY
- 48.59%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.60
- Avg Volume
- 471.6
Get TickerSpark's AI analysis on VIAP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 15, 10 | CRAVES FRED B | buy | 3,671,806 |
| Nov 15, 10 | CRAVES FRED B | buy | 60,495 |
| Apr 1, 10 | Wright Karen Steil | other | 0 |
| Apr 1, 10 | Wright Karen Steil | other | 40,000 |
| Apr 1, 10 | Wright Karen Steil | other | 9,300 |
| Apr 1, 10 | Wright Karen Steil | other | 6,691 |
| Mar 26, 10 | CRAVES FRED B | buy | 1,533,519 |
| Mar 26, 10 | CRAVES FRED B | buy | 25,265 |
| Mar 12, 09 | CRAVES FRED B | buy | 7,241,618 |
| Mar 12, 09 | CRAVES FRED B | buy | 119,308 |
Our VIAP coverage
Recent articles, reports, and earnings notes.
No research on VIAP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VIAP report →Similar companies
Peers in the same neighborhood.